Sanofi has announced its plans to buy more shares in US biotech, Regeneron Pharmaceuticals. The French drugmaker currently controls approximately 17% of Regeneron. Due to a long-term partnership ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

If Sanofi opts in to the other project, Regeneron will lead MUC16xCD3 bispecific development and marketing in the US. The companies will share development costs and profits.

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Sanofi is an innovative global healthcare company, ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in ... added to background maximal standard-of-care inhaled therapy in adults with uncontrolled COPD ...